Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747617 · ClinicalTrials.gov registry record · Phase 3
Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
A Phase 3 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT00747617 is a Phase 3 study that has completed, run by University of California, San Diego. The registered enrollment target is 25 participants.
The verdict
NCT00747617, a Phase 3 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
The mechanism for increased androgen production in women with polycystic ovary syndrome (PCOS) is not well understood. Excess androgen production by the ovary is stimulated by increased pituitary luteinizing hormone (LH) secretion in this disorder. The investigators hypothesize that in PCOS women ovarian theca cells, which are responsible for androgen synthesis, are more sensitive to LH stimulation compared to that of theca cells from normal women. To test this hypothesis, the investigators propose to conduct a dose-response study in which androgen responses to multiple doses of human chorionic gonadotgropin (hCG), an LH surrogate, will be assessed in PCOS and normal women.
Interventions
- DRUG recombinant human chorionic gonadotropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747617
The ClinicalTrials.gov registry entry for NCT00747617 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant human chorionic gonadotropin is the first listed.
NCT00747617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00747617 about?
NCT00747617 is a clinical study titled "Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)". The mechanism for increased androgen production in women with polycystic ovary syndrome (PCOS) is not well understood. Excess androgen production by the ovary is stimulated by increased pituitary luteinizing hormone (LH) secretion in this disorder. The investigators hypothesize that in PCOS women ov...
What is the current status of trial NCT00747617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2007-09. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00747617?
The interventions under investigation include: recombinant human chorionic gonadotropin (DRUG).
Who is sponsoring clinical trial NCT00747617?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.